COMPASS Pathways psilocybin therapy development

Biotechnology company COMPASS Pathways is advancing its lead candidate, COMP360, a synthetic psilocybin formulation designed to treat treatment-resistant depression. In mid-September 2026, the company reported a Q2 financial loss of $1.88 per share, missing analyst estimates, while noting that two Phase III trials had been completed with “highly statistically significant results.”

By October 2026, the company moved toward a rolling FDA submission for COMP360, expected to be completed by the end of the quarter. Clinical data presented indicates that 25% of patients showed a clinically meaningful response after one session, rising to 40% after a second dose, with benefits potentially lasting up to a year.

To support a potential commercial launch in 2027, CEO Kabir Nath indicated the company will adopt a “measured rollout strategy” to protect the broader psychedelic medicine sector. Preparations include developing a Risk Evaluation and Mitigation Strategy (REMS), investing in provider training, and engaging with the Centers for Medicare and Medicaid Services regarding reimbursement for clinical monitoring.